Achillion Pharmaceuticals Inc $2.79

up +0.18


16/4/2014 08:10 PM  |  NASDAQ : ACHN  
Industries : Drugs / Biotechnology
Get Trend Analysis Icon Get ACHN Trend Analysis - it has underperformed the S&P 500 by 80%

Partner Headlines

  1. Morning Gainers for Friday, March 14, 2014

    Benzinga
  2. Benzinga's Top #PreMarket Gainers

    Benzinga
  3. Achillion Reports HCV Pipeline Progress and Outlines 2014 HCV Milestones ...

    Benzinga
  4. Benzinga's Top #PreMarket Gainers

    Benzinga
  5. Benzinga's Top #PreMarket Gainers

    Benzinga
  6. Achillion's ACH-3422 Shows Compelling Preclinical Profile

    Benzinga
  7. Achillion Pharma Downgraded After Hepatitis C Setback

    IBD
  8. UPDATE: Piper Jaffray Downgrades Achillion Pharmaceuticals as Pipeline ...

    Benzinga
  9. Morning Market Losers

    Benzinga
  10. UPDATE: Bank of America Downgrades Achillion Pharmaceuticals Following ...

    Benzinga
  11. Benzinga's Top Downgrades

    Benzinga
  12. Achillion Pharma Announces Unable to Resolve Clinical Hold

    Benzinga
  13. These Three Speculative Companies Are Loved By Insiders and Institutions

    Benzinga
  14. Mid-Day Market Update: SolarCity Wins Big, SunPower Continues its Fall

    Benzinga
  15. Bank of America Merrill Lynch Reiterates Buy Rating, $13 PT on Achillion ...

    Benzinga
  16. Gilead Hep C Drug Meets Expectations In Phase 3 Trial

    IBD
  17. Mid-Day Market Update: Markets Slow Their Rally; JC Penney Spikes Lower

    Benzinga
  18. Achillion Provides Update on Clinical HCV Development Programs, Announces ...

    Benzinga
  19. Achillion Pharmaceuticals Inc. Reports Operating Results (10-Q)

    GuruFocus
  20. Achillion Pharmaceuticals Says Farewell to Single Digits

    SchaeffersResearch
  21. Benzinga's Top Pre-Market Gainers

    Benzinga
  22. Achillion Pharmaceuticals (ACHN) Up 14.3% After Upgrades

    MarketIntelligenceCenter
  23. UPDATE: Deutsche Bank Initiates Coverage on Achillion Pharmaceuticals with ...

    Benzinga
  24. UPDATE: Deutsche Bank Initiates Buy on Achillion Pharmaceuticals

    Benzinga
  25. Benzinga's Top Pre-Market Gainers

    Benzinga
  26. UPDATE: Piper Jaffray Reiterates Overweight Rating, Lowers PT on Achillion ...

    Benzinga
  27. Achillion to Raise $41.8 Million Through Registered Direct Offering

    Benzinga
  28. Speculator Raises the Bullish Stakes on Achillion Pharmaceuticals

    SchaeffersResearch
  29. Bristol-Myers' $2.5 Billion Acquisition of Inhibitex: Oh, Well

    YCharts
  30. Idenix's FDA Trouble Shakes Up Hep C Drug Stocks

    IBD
  31. Benzinga's Top Upgrades

    Benzinga
  32. Health Care Sector Wrap

    FoxBusiness
  33. Achillion Announces Resignation of Chief Medical Officer

    Benzinga
  34. UPDATE: UBS Investment Research Upgrades Achillion to Neutral; Balanced ...

    Benzinga
  35. UPDATE: Bank of America Raises Actuant's PT

    Benzinga
  36. Piper Jaffray: Achillion Pharmaceuticals Ended 2011 with $80M Cash

    Benzinga
  37. Gilead Sees Hep C Setback

    IBD
  38. Gilead Falls On Disappointing Hep C Drug Data; Analysts Remain Bullish

    Benzinga
  39. Achillion Pharmaceuticals Announces Virology Profile Following Treatment ...

    Benzinga
  40. Achillion Pharmaceuticals (ACHN) Loses 7.9% Despite Merger Speculation

    MarketIntelligenceCenter
  41. Benzinga's M&A Chatter for Wednesday February 8, 2012

    Benzinga
  42. Benzinga's Top Pre-Market Losers

    Benzinga
  43. Financial Breakfast: Morning News Summary for February 07, 2012

    Benzinga
  44. UPDATE: Bank of America Downgrades Achillion Pharmaceuticals to Underperform

    Benzinga
  45. Benzinga's M&A Chatter for Thursday February 2, 2012

    Benzinga
  46. Benzinga's M&A Chatter for Tuesday January 24, 2012

    Benzinga
  47. Afternoon Movers; Negative Euro News

    Benzinga
  48. Weekly CEO Sells Highlight: Achillion Pharmaceuticals Inc, Monster Beverage ...

    GuruFocus
  49. Benzinga's M&A Chatter for Friday January 20, 2012

    Benzinga
  50. End-of-Day Market Summary for January 20, 2012

    Benzinga
Trading Center